Previous Page  12 / 38 Next Page
Information
Show Menu
Previous Page 12 / 38 Next Page
Page Background

SOMATOSTATIN ANALOGS

Liver burden disease

PROMID

CLARINET

18.8% of patients 33% of patients

Rinke A, et al. Neuroendocrinology 2017;104:26–32

Caplin M, et al. N Engl J Med 2014; 371:224-233

Liver tumor load > 25%

OS in hepatic tumor load ≤ 10% vs > 10%